Welcome to the RCORP Corner! This page will house the various RCORP articles and blog posts, including the RCORP-TA Newsletter. You can find the various features below. Questions? Email trabolt@jbsinternational.com.
RCORP Corner
Best Practice of the Month
A dedicated monthly article to a relevant and timely medical or service-based best practice for RCORP grantees.
Up until recently, medical clinicians who wanted to prescribe buprenorphine were required to complete training and permission from the federal government in the form of the “X-Waiver.” In December 2022, Congress passed the Consolidated Appropriations Act (CAA), which eliminated the X-Waiver.[i],[ii] Any clinician with a DEA license to prescribe a Schedule III drug can now prescribe
Featured Grantee
Each month we choose an RCORP grantee to feature that is doing innovative and impactful work in their respective service area.
United Way of the Wabash Valley (UWWV), located in West Central Indiana, is a volunteer-led nonprofit organization that seeks to improve the lives of all individuals residing within the Wabash Valley. Click the title to learn more!
RCORP Blog
Guest writers and special blog posts will be regularly featured here in the RCORP Blog.
Thank you to the dozens of RCORP grantees who submitted to the 2022 "Power of RCORP" Photo Showcase! Click the title to see the
Staff Spotlight
Our new staff spotlights are a way for RCORP stakeholders to learn a bit more about the staff behind the scenes at JBS and HRSA.
Content Hubs
Content Hubs will house in-depth tools and resources for a variety of RCORP topic categories.
Xylazine, also referred to as “tranq,” is a non-opioid veterinary tranquilizer increasingly associated with overdose deaths in the United States. It is a central nervous system depressant and can cause respiratory depression. When used in combination with opioids such as fentanyl, it can have a synergistic effect and increase risk of overdose.